Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 05, 2015 1:26 AM ET

Biotechnology

Company Overview of Alvogen, Inc.

Company Overview

Alvogen, Inc. engages in the product development, contract manufacturing and research, and sale of generic and brand medicines, biosimilars, and OTC products. Its product portfolio comprises a range of molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology, and gastroenterology. The company focuses on niche generics, patches, controlled release, and narcotics in the form of solid oral dosage, soft gelatin capsules, modified release tablets, transdermals, creams, ointments, and injectables; promotes and distributes various biosimilar products for indications across several therapeutic areas; provides contract manufacturing, product development, ...

10 Bloomfield Avenue

Pine Brook, NJ 07058

United States

Founded in 2008

Phone:

973-796-3400

Fax:

973-796-3439

Key Executives for Alvogen, Inc.

Executive Chairman and Chief Executive Officer
Executive Vice President of Global Supply Chain
Chief Financial Officer and Member of Executive Board
Chief Operating Officer and Member of Executive Board
Member of Executive Board and Chief Executive Officer of Alvogen America
Age: 45
Compensation as of Fiscal Year 2015.

Alvogen, Inc. Key Developments

Alvogen, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 10:00 AM

Alvogen, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 10:00 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.

Alvogen, Inc. Presents at UBS Global Healthcare Conference, May-19-2014

Alvogen, Inc. Presents at UBS Global Healthcare Conference, May-19-2014 . Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States.

Alvogen, Inc. Announces Launch of InflectraTM) (Infliximab) into Central and Eastern Europe

Alvogen, Inc. announced the launch of Inflectra(TM) (Infliximab) into Central and Eastern Europe. Inflectra(TM), Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis. Alvogen and Hospira formed a strategic partnership in 2011 to provide the quality products and services for customers and patients throughout Central and Eastern Europe (CEE). This alliance enables to provide increased access to the newest biosimilar drugs with technology. Inflectra(TM) is a biosimilar medicine to the reference medicinal product, Remicade(TM) (Infliximab), and is the first monoclonal antibody (mAb) to be approved through the European Medicines Agency (EMA) biosimilars regulatory pathway. Remicade(TM) recorded European sales of over USD 2 billion in 2012. Alvogen will market the product in Bulgaria, Croatia, Estonia, Hungary, Latvia, Lithuania, Poland, and Romania. The use of biologic medicines has led to vast improvements in the efficient treatment of conditions such as RA and IBD (inflammatory bowel disease), but these drugs are also responsible for some of the medicinal costs for many countries. The introduction of biosimilar mAbs in Europe is expected to deliver savings of up to EUR 20.4 billion by 2020. In partnership with Hospira, Alvogen has been marketing biosimilars in Central & Eastern Europe for a number of years, with great success. Partnering with Hospira gives Alvogen access to a well established biosimilar pipeline. Hospira's biosimilar portfolio includes Inflectra(TM) as well as two other currently marketed products in the areas of nephrology and oncology. In addition, Hospira plans to launch a number of new biosimilar monoclonal antibodies, one of which is currently in late stage development. Together, Alvogen and Hospira share the commitment to deliver the quality products and services to its customers and patients.

Similar Private Companies By Industry

Company Name Region
Inhibitex, Inc. United States
Genome Corp. United States
Tidal Air, Inc. United States
Dragonfly Sciences, Inc. United States
Ichor Biotechnologies, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
June 22, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Alvogen, Inc., please visit www.alvogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.